<DOC>
	<DOCNO>NCT01098890</DOCNO>
	<brief_summary>The propose study evaluate acceleration clearance intraventricular blood ( IVH ) subarachnoid hemorrhage ( SAH ) follow rupture intracranial aneurysm , thereby ameliorate complication , cerebral vasospasm , hydrocephalus intracranial hypertension . The primary objective : 1 . Estimate rate variance hematoma clearance follow aneurysmal SAH , thereby facilitate sample size determination subsequent large study ; 2 . Assess feasibility randomize control trial intraventricular tissue plasminogen activator ( TPA ) among patient SAH ( enrollment rate , ability blind investigator , protocol compliance ) ; 3 . Confirm safety intraventricular TPA .</brief_summary>
	<brief_title>Intraventricular Tissue Plasminogen Activator ( tPA ) Management Aneurysmal Subarachnoid Hemorrhage</brief_title>
	<detailed_description>Outcome Measures : Safety assess adverse event , hemorrhagic complication development ventriculostomy-related infection . The volume clearance intracranial blood determine ( ml ) use computerized software , well validate semi-quantitative ordinal scale ( SAH Sum Score , Modified Graeb Score ) . The amount IVH SAH assess baseline ( day 0 ) , 72 hour treatment onset , post-SAH day 8 . Additional secondary outcome include : 1 . The occurrence vasospasm , determine use transcranial Doppler ultrasonography 2 . The occurrence radiographic vasospasm , use CT angiography . 3 . The occurrence `` clinical '' ( symptomatic ) vasospasm 4 . The rate catheter-related central nervous system infection 5 . Levels cytokine , endothelin matrix metalloproteases cerebrospinal fluid ( CSF ) plasma 6 . Levels fibrin-derived product ( FDP ) , TPA plasminogen-activator inhibitor CSF 7 . Levels S100Î² neuron-specific enolase ( NSE ) CSF serum 8 . Intracranial pressure 9 . Volume CSF drainage 10 . Extended Glasgow Outcome Scale , modify Rankin scale , EuroQOL 6 month post-SAH 11 . Duration ventriculostomy require ; need permanent shunt 12 . Fever burden</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Adult patient ( &gt; 18 year old ) proven rupture cerebral aneurysm Aneurysm / treat coil embolization EVD / place part routine care Modified Fisher score 4 ( cisternal blood &gt; 1 mm thick concomitant IVH ) CT scan EVD placement show `` stability '' increase amount intracranial blood ( Note : sometimes layer blood , especially occipital horn lateral ventricle , develops first 2448 hour rupture aneurysm due circulation blood CSF necessarily constitute exclusion criterion ) . Study drug administer within 72 hour time SAH . Concern express endovascular neurosurgeon / interventional radiologist aneurysm incompletely treat / isolate coil embolization . Patient require craniotomy clip culprit aneurysm . CT scan perform postEVD insertion OR postcoiling show increase amount intracranial blood . Uncorrected coagulation disturbance ( INR &gt; 1.5 , PTT &gt; 45 ) ; correction permit ( coagulation disturbance develop study , subsequent dos TPA simply withhold coagulation correct ) . Uncorrected thrombocytopenia ( platelet &lt; 50,000 ) ; correction platelet transfusion permit . Involvement another clinical trial Uncontrolled active internal hemorrhage Known allergy study drug Patient pregnant Any condition investigator believe would place subject risk include study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>